Designs of preoperative biomarkers trials in oncology: A systematic review of the literature

Annals of Oncology

Volumn 26, Issue 12, 2015, Pages 2419-2428

  Marous, M ^a   Bieche, I ^a   Paoletti, X ^a,b   Alt, M ^a   Razak, A R A ^c   Stathis, A ^d   Kamal, M ^a   Le Tourneau, C ^a,e  

^a INSTITUT CURIE   (France)

^b INSERM U900   (France)

^c UNIVERSITY OF TORONTO   (Canada)

^d ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Biomarker; Oncology; Pharmacodynamic; Predictive; Preoperative; Trials

Indexed keywords

ANASTROZOLE; ANTIANDROGEN; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CUSTIRSEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ESTRAMUSTINE; EVEROLIMUS; FAMOTIDINE; FIGITUMUMAB; FLUOROURACIL; GEFITINIB; LAPATINIB; LETROZOLE; METFORMIN; MITOXANTRONE; OBLIMERSEN; OLAPARIB; PACLITAXEL; RALOXIFENE; RAPAMYCIN; TAMOXIFEN; TRASTUZUMAB; UNINDEXED DRUG; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; FEASIBILITY STUDY; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; ONCOLOGY; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZATION; STOMACH CANCER; STUDY DESIGN; SYSTEMATIC REVIEW; TREATMENT DURATION; METABOLISM; NEOPLASMS; PREOPERATIVE CARE; PROCEDURES;

BIOMARKERS, TUMOR; CLINICAL TRIALS AS TOPIC; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PREOPERATIVE CARE;

EID: 84949950667     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv378     Document Type: Article

References (63)

1. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
2. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
3. Lièvre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
4. Goulart B, Clark JW, Pien HH et al. Trends in use and role of biomarkers in phase I oncology trials. Clin Cancer Res 2007; 13: 6719-6726.
5. Dancey JE, Dobbin KK, Groshen S et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010; 16: 1745-1755.
6. Ratain MJ. Bar the windows but open the door to randomization. J Clin Oncol 2010; 28: 3104-3106.
7. Dowsett M, Smith I, Robertson J et al. Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. J Natl Cancer Inst Monogr 2011; 2011: 120-123.
8. Dowling RJ, Niraula S, Chang MC et al. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res 2015; 17: 540.
9. Guarneri V, Dieci MV, Bisagni G et al. Preoperative carboplatin-paclitaxelbevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study. Ann Surg Oncol 2015; 22: 2881-2887.
10. Hadad SM, Coates P, Jordan LB et al. Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial. Breast Cancer Res Treat 2015; 150: 149-155.
11. Shigematsu H, Kadoya T, Masumoto N et al. The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial. Clin Breast Cancer 2015; 15: 110-116.
12. Leary A, Evans A, Johnston SR et al. Antiproliferative effect of lapatinib in HER2- positive and HER2-negative/HER3-high breast cancer: results of the presurgical randomized MAPLE trial (CRUK E/06/039). Clin Cancer Res 2015; 21: 2932-2940.
13. Kalinsky K, Crew KD, Refice S et al. Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest 2014; 32: 150-157.
14. DeCensi A, Puntoni M, Gandini S et al. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat 2014; 148: 81-90.
15. Serrano D, Lazzeroni M, Gandini S et al. A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res 2013; 15: R47.
16. Bundred N, Gardovskis J, Jaskiewicz J et al. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. Invest New Drugs 2013; 31: 949-958.
17. Guarneri V, Generali DG, Frassoldati A et al. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. J Clin Oncol 2014; 32: 1050-1057.
18. Holmes FA, Espina V, Liotta LA et al. Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. BMC Res Notes 2013; 6: 507.
19. Cazzaniga M, DeCensi A, Pruneri G et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer 2013; 109: 2792-2797.
20. Ohno S, Chow LW, Sato N et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat 2013; 142: 69-80.
21. Sánchez-Rovira P, Seguí MA, Llombart A et al. Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response. Clin Transl Oncol 2013; 15: 810-817.
22. Niraula S, Dowling RJ, Ennis M et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 2012; 135: 821-830.
23. Guarneri V, Frassoldati A, Bottini A et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2- positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012; 30: 1989-1995.
24. Bonanni B, Puntoni M, Cazzaniga M et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012; 30: 2593-2600.
25. Hadad S, Iwamoto T, Jordan L et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011; 128: 783-794.
26. Macaskill EJ, Bartlett JM, Sabine VS et al. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. Breast Cancer Res Treat 2011; 128: 725-734.
27. Decensi A, Puntoni M, Pruneri G et al. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res (Phila) 2011; 4: 1181-1189.
28. Rom J, von Minckwitz G, Marmé F et al. Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer. Ann Oncol 2009; 20: 1829-1835.
29. Van Nes JG, Putter H, Julien JP et al. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat 2009; 115: 101-113.
30. Guix M, Granja Nde M, Meszoely I et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol 2008; 26: 897-906.
31. Guarneri V, Frassoldati A, Ficarra G et al. Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. Breast Cancer Res Treat 2008; 110: 127-134.
32. Smith IE, Walsh G, Skene A et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007; 25: 3816-3822.
33. Rocca A, Peruzzotti G, Ghisini R et al. A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. Anticancer Drugs 2006; 17: 1201-1209.
34. Polychronis A, Sinnett HD, Hadjiminas D et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 2005; 6: 383-391.
35. Parshad R, Hazrah P, Kumar S et al. Effect of preoperative short course famotidine on TILs and survival in breast cancer. Indian J Cancer 2005; 42: 185-190.
36. Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23: 5108-5116.
37. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A et al. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 2004; 10: 2336-2343.
38. Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10: 5650-5655.
39. Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004; 10: 6622-6628.
40. Bajetta E, Celio L, Di Leo A et al. Effects of short-term pre-operative tamoxifen on steroid receptor and Ki-67 expression in primary breast cancer: an immunocytochemical study. Int J Oncol 1998; 12: 853-858.
41. Joshua AM, Zannella VE, Downes MR et al. A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis 2014; 17: 252-258.
42. Chi KN, Gleave ME, Fazli L et al. A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res 2012; 18: 3407-3413.
43. Garzotto M, Higano CS, O'Brien C et al. Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer 2010; 116: 1699-1708.
44. Armstrong AJ, Netto GJ, Rudek MA et al. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res 2010; 16: 3057-3066.
45. Chi KN, Eisenhauer E, Fazli L et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 20-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005; 97: 1287-1296.
46. Van de Voorde WM, Elgamal AA, Van Poppel HP et al. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies. Cancer 1994; 74: 3164-3175.
47. Kapoor S, Pal S, Sahni P et al. Effect of pre-operative short course famotidine on tumor infiltrating lymphocytes in colorectal cancer: a double blind, placebo controlled, prospective randomized study. J Surg Res 2005; 129: 172-175.
48. Kelly MD, King J, Cherian M et al. Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumorassociated lymphocytes. Cancer 1999; 85: 1658-1663.
49. Brivio F, Lissoni P, Barni S et al. Effects of a preoperative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: a phase 2 study. Eur J Surg 1993; 159: 43-47.
50. Gross ND, Bauman JE, Gooding WE et al. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clin Cancer Res 2014; 20: 3289-3298.
51. Schmitz S, Hamoir M, Reychler H et al. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck. Ann Oncol 2013; 24: 2261-2266.
52. Thomas F, Rochaix P, Benlyazid A et al. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res 2007; 13: 7086-7092.
53. Hirakawa M, Sato Y, Ohnuma H et al. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker. Cancer Chemother Pharmacol 2013; 71: 789-797.
54. Romano F, Piacentini MG, Franciosi C et al. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients. Hepatogastroenterology 2004; 51: 1872-1876.
55. Eriguchi M, Osada I, Fujii Y et al. Pilot study for preoperative administration of l-OHP to patients with advanced scirrhous type gastric cancer. Biomed Pharmacother 1997; 51: 217-220.
56. Altorki N, Lane ME, Bauer T et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 2010; 28: 3131-3137.
57. Haura EB, Sommers E, Song L et al. A pilot study of preoperative gefitinib for earlystage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. J Thorac Oncol 2010; 5: 1806-1814.
58. Lara-Guerra H, Waddell TK, Salvarrey MA et al. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J Clin Oncol 2009; 27: 6229-6236.
59. Endo H, Saito T, Kenjo A et al. Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients. J Hepatobiliary Pancreat Sci 2012; 19: 465-475.
60. Uggeri F, Caprotti R, De Grate L et al. Short-term preoperative IL-2 immunotherapy in operable pancreatic cancer: a randomized study. Hepatogastroenterology 2009; 56: 861-865.
61. Colombo N, Formelli F, Cantù MG et al. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 1914-1919.
62. Schuler KM, Rambally BS, DiFurio MJ et al. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med 2015; 4: 161-173.
63. McAuliffe JC, Hunt KK, Lazar AJ et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009; 16: 910-919.